Biophytis

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million

Biophytis extends its contract with Atlas to secure financing for its business activities